<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01986556</url>
  </required_header>
  <id_info>
    <org_study_id>RDEA594-129</org_study_id>
    <nct_id>NCT01986556</nct_id>
  </id_info>
  <brief_title>Lesinurad Tablet Relative Bioavailability</brief_title>
  <official_title>A Phase 1, Randomized, Open-Label, Crossover Study in Healthy Adult Male Subjects to Assess the Relative Bioavailability of Lesinurad Tablets Manufactured at Two Different Sites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardea Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ardea Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the relative bioavailability of lesinurad tablets, manufactured at two
      different sites.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A change in manufacturing site of lesinurad tablets has been implemented. This study is
      intended to evaluate the clinical comparability of lesinurad tablets manufactured at the two
      different sites by assessing relevant clinical Pharmacokinetics (PK) parameters.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK profile of lesinurad from plasma</measure>
    <time_frame>Day 1 and Day 5</time_frame>
    <description>PK endpoints in terms of maximum observed concentration (Cmax); time of occurrence of maximum observed concentration (Tmax); area under the plasma concentration time curve (AUC); and apparent terminal half-life (t1/2).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>5 weeks</time_frame>
    <description>Changes in Laboratory, Electrocardiogram and Vital Signs Parameters</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lesinurad 400 mg Fasted (Site 1 and Site 2, Lot A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot A) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lesinurad 400 mg Fed (Site 1 and Site 2, Lot A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot A) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lesinurad 400 mg Fasted (Site 1 and Site 2, Lot B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot B) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lesinurad 400 mg Fed (Site 1 and Site 2, Lot B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot B) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot B)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lesinurad 400 mg (Site 1)</intervention_name>
    <arm_group_label>Lesinurad 400 mg Fasted (Site 1 and Site 2, Lot A)</arm_group_label>
    <arm_group_label>Lesinurad 400 mg Fed (Site 1 and Site 2, Lot A)</arm_group_label>
    <arm_group_label>Lesinurad 400 mg Fasted (Site 1 and Site 2, Lot B)</arm_group_label>
    <arm_group_label>Lesinurad 400 mg Fed (Site 1 and Site 2, Lot B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lesinurad 400 mg (Site 2, Lot A)</intervention_name>
    <arm_group_label>Lesinurad 400 mg Fasted (Site 1 and Site 2, Lot A)</arm_group_label>
    <arm_group_label>Lesinurad 400 mg Fed (Site 1 and Site 2, Lot A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lesinurad 400 mg (Site 2, Lot B)</intervention_name>
    <arm_group_label>Lesinurad 400 mg Fasted (Site 1 and Site 2, Lot B)</arm_group_label>
    <arm_group_label>Lesinurad 400 mg Fed (Site 1 and Site 2, Lot B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has a body weight ≥ 50 kg (110 lbs) and a body mass index (BMI) ≥ 18 and ≤ 40
             kg/m2.

          -  Subject has a Screening sUA value ≤ 7.0 mg/dL.

          -  Subject is free of any clinically significant disease that requires a physician's care
             and/or would interfere with study evaluations or procedures.

          -  Subject has no clinically relevant abnormalities in vital signs, ECG, physical
             examination or safety laboratory values per the Investigator's judgment.

        Exclusion Criteria:

          -  Subject has a history or clinical manifestations of significant metabolic,
             hematological, pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic,
             renal, urological, or psychiatric disorders.

          -  Subject has a history or suspicion of kidney stones.

          -  Subject has a history of asthma.

          -  Subject has undergone major surgery within 3 months prior to Day 1.

          -  Subject has donated blood or experienced significant blood loss (&gt; 450 mL) within 12
             weeks prior to Day 1 or gave a plasma donation within 4 weeks prior to the Screening
             visit.

          -  Subject has inadequate venous access or unsuitable veins for repeated venipuncture.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Hall, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ardea Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2013</study_first_submitted>
  <study_first_submitted_qc>November 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2013</study_first_posted>
  <last_update_submitted>September 19, 2014</last_update_submitted>
  <last_update_submitted_qc>September 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lesinurad</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

